Dr. Becerra on Ribociclib/Letrozole in ER+/HER2- Breast Cancer
Carlos Becerra, MD, physician, Texas Oncology, discusses a study examining the combination of ribociclib and letrozole in patients with ER-positive, HER2-negative advanced breast cancer.
Carlos Becerra, MD, physician, Texas Oncology, discusses a study examining the combination of ribociclib and letrozole in patients with ER-positive, HER2-negative advanced breast cancer.
To enroll on the trial, patients must have progressed on estrogen receptor inhibitors, Becerra explains. Patients were treated with the combination to determine whether treatment with the CDK 4/6 inhibitor would prevent resistance to letrozole.
Results showed that the combination demonstrated clinical activity as well as an acceptable safety profile in patients, with an overall response rate of 39%.
